Akebia Therapeutics (AKBA) Other financing activities (2015 - 2026)
Akebia Therapeutics' (AKBA) quarterly Other financing activities came in at $20000.0 in Q1 2026, down 95.85% year-on-year from $482000.0 in Q1 2025, and down 86.84% on a QoQ basis from $152000.0 in Q3 2025.
Akebia Therapeutics (AKBA) Other financing activities (2015 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 11 years of Other financing activities data on file, last reported at $20000.0 in Q1 2026.
- On a quarterly basis, Other financing activities fell 95.85% year-over-year to $20000.0 in Q1 2026; TTM through Mar 2026 was -$232000.0, a 146.87% decrease from a year earlier, with the FY2025 full-year figure at $230000.0, up 49.35% from the prior year.
- Other financing activities for Q1 2026 stood at $20000.0, down from $152000.0 in the prior quarter.
- Over the last five years, Other financing activities for AKBA reached as high as $482000.0 in Q1 2025 and fell as low as -$404000.0 in Q2 2025.
- Historically, Other financing activities has averaged $58214.3 across 5 years, with a median of $17000.0 in 2024.
- On a YoY basis, Other financing activities climbed as much as 7700.0% in 2025 and fell as far as 2985.71% in 2025.
- Year by year, Other financing activities stood at $343000.0 in 2022, then tumbled by 99.71% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then surged by 15100.0% to $152000.0 in 2025, then sank by 86.84% to $20000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $20000.0 in Q1 2026, $152000.0 in Q3 2025, and -$404000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |